{"hands_on_practices": [{"introduction": "Understanding the performance of a diagnostic test in a real-world clinical setting is a cornerstone of evidence-based medicine. While sensitivity and specificity measure a test's intrinsic accuracy, their true utility is revealed through predictive values, which depend heavily on the prevalence of the disease in the target population. This exercise provides hands-on practice in applying Bayes' theorem to calculate the Positive Predictive Value ($PPV$) and Negative Predictive Value ($NPV$) for alpha-fetoprotein ($AFP$) in a high-risk surveillance cohort, a fundamental skill for interpreting biomarker results in clinical practice [@problem_id:4380795].", "problem": "A hospital implements a surveillance program for hepatocellular carcinoma (HCC) in a cohort of patients with cirrhosis. Alpha-fetoprotein (AFP) is used as a binary screening test with a fixed threshold. In this cohort, the following performance characteristics and disease frequency are well established from prior validation work: sensitivity $0.60$, specificity $0.90$, and disease prevalence $0.20$. Using only the core probabilistic definitions from diagnostic test evaluation and Bayes’ theorem, derive expressions for the positive predictive value (PPV), defined as $P(\\text{Disease} \\mid \\text{Test positive})$, and the negative predictive value (NPV), defined as $P(\\text{No disease} \\mid \\text{Test negative})$, in terms of sensitivity, specificity, and prevalence. Then compute the numerical values for PPV and NPV for this cohort.\n\nReport your final answer as a row vector $[PPV \\; NPV]$ rounded to three significant figures and expressed as decimals (do not use a percent sign).", "solution": "The problem statement is evaluated as valid, as it is scientifically grounded in probability theory, well-posed with sufficient information, and objective in its language. We may therefore proceed with a formal solution.\n\nLet us define the events and probabilities based on the provided information.\nLet $D$ be the event that a patient has hepatocellular carcinoma (disease).\nLet $D^c$ be the event that a patient does not have the disease.\nLet $T^+$ be the event that the alpha-fetoprotein (AFP) test result is positive.\nLet $T^-$ be the event that the test result is negative.\n\nThe problem provides the following probabilities:\nThe sensitivity of the test, $\\text{Se}$, is the probability of a positive test given the patient has the disease:\n$$P(T^+ \\mid D) = \\text{Se} = 0.60$$\nThe specificity of the test, $\\text{Sp}$, is the probability of a negative test given the patient does not have the disease:\n$$P(T^- \\mid D^c) = \\text{Sp} = 0.90$$\nThe prevalence of the disease, $P_{\\text{prev}}$, is the prior probability of a patient having the disease in the cohort:\n$$P(D) = P_{\\text{prev}} = 0.20$$\n\nFrom these, we can derive complementary probabilities:\nThe probability of a patient not having the disease is:\n$$P(D^c) = 1 - P(D) = 1 - P_{\\text{prev}} = 1 - 0.20 = 0.80$$\nThe false positive rate is the probability of a positive test given the patient does not have the disease:\n$$P(T^+ \\mid D^c) = 1 - P(T^- \\mid D^c) = 1 - \\text{Sp} = 1 - 0.90 = 0.10$$\nThe false negative rate is the probability of a negative test given the patient has the disease:\n$$P(T^- \\mid D) = 1 - P(T^+ \\mid D) = 1 - \\text{Se} = 1 - 0.60 = 0.40$$\n\nThe first part of the task is to derive an expression for the positive predictive value ($\\text{PPV}$), defined as $P(D \\mid T^+)$, in terms of sensitivity, specificity, and prevalence. We apply Bayes' theorem:\n$$\\text{PPV} = P(D \\mid T^+) = \\frac{P(T^+ \\mid D) P(D)}{P(T^+)}$$\nThe denominator, $P(T^+)$, is the total probability of a positive test result. We can expand it using the law of total probability:\n$$P(T^+) = P(T^+ \\mid D) P(D) + P(T^+ \\mid D^c) P(D^c)$$\nSubstituting the definitions of sensitivity, specificity, and prevalence:\n$$P(T^+) = (\\text{Se} \\times P_{\\text{prev}}) + ((1 - \\text{Sp}) \\times (1 - P_{\\text{prev}}))$$\nSubstituting this expression back into the formula for $\\text{PPV}$, we obtain the general expression:\n$$\\text{PPV} = \\frac{\\text{Se} \\times P_{\\text{prev}}}{(\\text{Se} \\times P_{\\text{prev}}) + (1 - \\text{Sp})(1 - P_{\\text{prev}})}$$\n\nThe second part of the task is to derive an expression for the negative predictive value ($\\text{NPV}$), defined as $P(D^c \\mid T^-)$, in terms of the same parameters. We again apply Bayes' theorem:\n$$\\text{NPV} = P(D^c \\mid T^-) = \\frac{P(T^- \\mid D^c) P(D^c)}{P(T^-)}$$\nThe denominator, $P(T^-)$, is the total probability of a negative test result, which can be expanded using the law of total probability:\n$$P(T^-) = P(T^- \\mid D) P(D) + P(T^- \\mid D^c) P(D^c)$$\nSubstituting the definitions of sensitivity, specificity, and prevalence:\n$$P(T^-) = ((1 - \\text{Se}) \\times P_{\\text{prev}}) + (\\text{Sp} \\times (1 - P_{\\text{prev}}))$$\nSubstituting this into the formula for $\\text{NPV}$, we obtain the general expression:\n$$\\text{NPV} = \\frac{\\text{Sp} \\times (1 - P_{\\text{prev}})}{((1 - \\text{Se}) \\times P_{\\text{prev}}) + \\text{Sp}(1 - P_{\\text{prev}})}$$\n\nNow, we compute the numerical values for $\\text{PPV}$ and $\\text{NPV}$ using the given data: $\\text{Se} = 0.60$, $\\text{Sp} = 0.90$, and $P_{\\text{prev}} = 0.20$.\n\nFor the $\\text{PPV}$:\n$$\\text{PPV} = \\frac{0.60 \\times 0.20}{(0.60 \\times 0.20) + (1 - 0.90)(1 - 0.20)}$$\n$$\\text{PPV} = \\frac{0.12}{0.12 + (0.10)(0.80)}$$\n$$\\text{PPV} = \\frac{0.12}{0.12 + 0.08}$$\n$$\\text{PPV} = \\frac{0.12}{0.20} = 0.60$$\n\nFor the $\\text{NPV}$:\n$$\\text{NPV} = \\frac{0.90 \\times (1 - 0.20)}{((1 - 0.60) \\times 0.20) + 0.90(1 - 0.20)}$$\n$$\\text{NPV} = \\frac{0.90 \\times 0.80}{(0.40 \\times 0.20) + (0.90 \\times 0.80)}$$\n$$\\text{NPV} = \\frac{0.72}{0.08 + 0.72}$$\n$$\\text{NPV} = \\frac{0.72}{0.80} = 0.90$$\n\nThe problem requires the final answer to be rounded to three significant figures. The calculated values are $\\text{PPV} = 0.60$ and $\\text{NPV} = 0.90$. To express these with three significant figures, we write them as $0.600$ and $0.900$, respectively. The final answer is to be reported as a row vector.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.600  0.900\n\\end{pmatrix}\n}\n$$", "id": "4380795"}, {"introduction": "Moving from screening to definitive diagnosis, the pathologist's primary task is to interpret tissue biopsies. This is particularly challenging in cirrhotic livers, where benign regenerative nodules can mimic well-differentiated hepatocellular carcinoma. The diagnosis hinges on distinguishing reactive cytologic atypia from the true architectural disorganization of malignancy. This problem challenges you to step into the role of a pathologist by constructing and applying a formal diagnostic algorithm, learning to weigh different histologic features to make a diagnosis that is both sensitive and specific [@problem_id:4380843].", "problem": "You are tasked with formalizing a rule-based diagnostic algorithm for hepatocellular carcinoma (HCC) on core biopsy in a cirrhotic liver using three histologic features measurable on routine stains: increased nuclear-to-cytoplasmic ratio (N:C), nucleolar prominence, and thickened hepatocyte plates (trabeculae). Base your construction on the following foundational definitions and well-tested observations in hepatopathology: (i) malignancy is inferred from a combination of cytologic atypia and architectural disorganization; (ii) reactive hepatocytes in cirrhosis may show cytologic atypia without frank architectural disruption; (iii) hepatocyte plates thicker than normal reflect architectural derangement, with plates greater than $3$ cells across being strongly associated with neoplasia; (iv) normal or regenerative hepatocytes typically have a median $N:C$ near $0.3$ to $0.4$, whereas malignant hepatocytes often have a median $N:C$ exceeding $0.5$ to $0.6$; (v) prominent nucleoli occur in a minority of benign regenerative settings but are substantially more frequent in malignancy. You must set explicit decision thresholds on each feature and specify logical combinations that trigger an HCC diagnosis.\n\nYou have the following empirical baselines from the literature-quality observations to guide threshold selection: in cirrhotic regenerative nodules, plates greater than $3$ cells across are virtually absent across low-power fields (typically less than $1\\%$ of fields), median $N:C$ rarely exceeds $0.45$, and cells with prominent nucleoli comprise less than $5\\%$ of hepatocytes; in established hepatocellular carcinoma, plates greater than $3$ cells across occupy at least $15\\%$ to $20\\%$ of low-power fields in most cases, median $N:C$ is usually greater than $0.6$, and cells with prominent nucleoli comprise at least $20\\%$ of tumor cells in a substantial fraction of cases.\n\nA new cirrhotic core biopsy is evaluated as follows: $20$ nonoverlapping low-power fields are surveyed; in $6$ of $20$ fields ($30\\%$), hepatocyte plates exceed $3$ cells in thickness. A count of $200$ lesional hepatocytes yields a median $N:C$ of $0.55$, and $25\\%$ of cells show prominent, easily visible nucleoli.\n\nYou aim to select the single best algorithm below that: (a) encodes explicit thresholds for the three features; (b) achieves at least $95\\%$ specificity against regenerative nodules by prioritizing architectural abnormality over purely cytologic atypia; and (c) classifies the present biopsy as HCC. Which algorithm best satisfies these aims?\n\nA. Diagnose HCC if any $2$ of the following $3$ criteria are met: median $N:C \\ge 0.50$; nucleolar prominence in $\\ge 15\\%$ of cells; plates greater than $3$ cells across in $\\ge 20\\%$ of low-power fields. Otherwise, do not diagnose HCC.\n\nB. Diagnose HCC if plates greater than $3$ cells across are present in $\\ge 15\\%$ of low-power fields and at least $1$ of the following is present: median $N:C \\ge 0.55$ or nucleolar prominence in $\\ge 20\\%$ of cells. Otherwise, do not diagnose HCC.\n\nC. Diagnose HCC if any $1$ of the following is present: median $N:C \\ge 0.55$ or nucleolar prominence in $\\ge 20\\%$ of cells or plates greater than $3$ cells across in $\\ge 10\\%$ of low-power fields. Otherwise, do not diagnose HCC.\n\nD. Diagnose HCC only if all $3$ of the following stricter thresholds are met: median $N:C \\ge 0.60$; nucleolar prominence in $\\ge 25\\%$ of cells; plates greater than $3$ cells across in $\\ge 30\\%$ of low-power fields. Otherwise, do not diagnose HCC.", "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the principles of histopathology, well-posed as a logical selection task, and objective in its language and data. All provided information is self-contained and sufficient to evaluate the proposed algorithms against the stated criteria.\n\nThe task is to select the best diagnostic algorithm from the given options based on three specific aims. The algorithm must formalize the diagnosis of hepatocellular carcinoma (HCC) using three features: thickened hepatocyte plates ($P_{\\text{thick}}$), increased nuclear-to-cytoplasmic ratio ($N:C$), and nucleolar prominence ($N_{\\text{prom}}$).\n\nThe aims for the algorithm are:\n(a) It must have explicit, quantitative thresholds.\n(b) It must achieve at least $95\\%$ specificity against regenerative nodules by prioritizing architectural abnormality over purely cytologic atypia. This is a crucial constraint, based on the provided principle that reactive hepatocytes in cirrhosis can show cytologic atypia (increased $N:C$ ratio, prominent nucleoli) without being malignant. Therefore, architectural disorganization (thickened plates) should be a primary or mandatory finding.\n(c) It must classify the provided case biopsy as HCC.\n\nThe data for the case biopsy are:\n- Thickened plates ($P_{\\text{thick}}$): Plates thicker than $3$ cells are found in $6$ of $20$ low-power fields, which is $30\\%$.\n- Nuclear-to-cytoplasmic ratio ($N:C$): The median $N:C$ is $0.55$.\n- Nucleolar prominence ($N_{\\text{prom}}$): Prominent nucleoli are seen in $25\\%$ of cells.\n\nThe empirical baselines for benign regenerative nodules, which the algorithm should not misclassify as HCC, are:\n- $P_{\\text{thick}}  1\\%$ of fields.\n- Median $N:C$ rarely exceeds $0.45$.\n- $N_{\\text{prom}}  5\\%$ of hepatocytes.\n\nWe will now evaluate each option against the three aims.\n\n**Option A:**\n- **Algorithm:** Diagnose HCC if any $2$ of the following $3$ criteria are met: median $N:C \\ge 0.50$; $N_{\\text{prom}} \\ge 15\\%$; $P_{\\text{thick}} \\ge 20\\%$.\n- **Evaluation:**\n    1. **Aim (a) - Explicit Thresholds:** This aim is met. The thresholds are $0.50$, $15\\%$, and $20\\%$.\n    2. **Aim (c) - Classify Case as HCC:**\n        - Is median $N:C \\ge 0.50$? Yes, $0.55 \\ge 0.50$.\n        - Is $N_{\\text{prom}} \\ge 15\\%$? Yes, $25\\% \\ge 15\\%$.\n        - Is $P_{\\text{thick}} \\ge 20\\%$? Yes, $30\\% \\ge 20\\%$.\n        All three criteria are met. Since only $2$ are required, this algorithm diagnoses the case as HCC. This aim is met.\n    3. **Aim (b) - Specificity  Prioritizing Architecture:** This algorithm allows for an HCC diagnosis if the two cytologic criteria (median $N:C \\ge 0.50$ and $N_{\\text{prom}} \\ge 15\\%$) are met, even if the architectural criterion ($P_{\\text{thick}} \\ge 20\\%$) is not. This directly violates the requirement to prioritize architecture, as it would permit a diagnosis based on cytologic atypia alone, which can be seen in non-malignant reactive states. This leads to poor specificity. This aim is not met.\n- **Verdict:** Incorrect. The algorithm fails to satisfy Aim (b) by not prioritizing architectural abnormality, leading to a potential loss of specificity.\n\n**Option B:**\n- **Algorithm:** Diagnose HCC if $P_{\\text{thick}} \\ge 15\\%$ AND at least one of the following is present: median $N:C \\ge 0.55$ or $N_{\\text{prom}} \\ge 20\\%$.\n- **Evaluation:**\n    1. **Aim (a) - Explicit Thresholds:** This aim is met. The thresholds are $15\\%$, $0.55$, and $20\\%$.\n    2. **Aim (c) - Classify Case as HCC:**\n        - First, check the mandatory architectural criterion: Is $P_{\\text{thick}} \\ge 15\\%$? Yes, $30\\% \\ge 15\\%$.\n        - Second, check the cytologic criteria (at least one must be met): Is median $N:C \\ge 0.55$? Yes, $0.55 \\ge 0.55$. Is $N_{\\text{prom}} \\ge 20\\%$? Yes, $25\\% \\ge 20\\%$.\n        Since the mandatory architectural criterion and both cytologic criteria are met, this algorithm diagnoses the case as HCC. This aim is met.\n    3. **Aim (b) - Specificity  Prioritizing Architecture:** The logical structure of this rule is `(Architectural criterion) AND (at least one Cytologic criterion)`. This explicitly makes architectural abnormality a prerequisite for diagnosis, thus satisfying the instruction to prioritize it. A case with only cytologic atypia would not be diagnosed as HCC. Furthermore, the thresholds ($15\\%$ for $P_{\\text{thick}}$, $0.55$ for $N:C$, $20\\%$ for $N_{\\text{prom}}$) are set well above the upper limits for regenerative nodules ($1\\%$, $0.45$, $5\\%$, respectively), ensuring high specificity. This aim is met.\n- **Verdict:** Correct. This algorithm satisfies all three aims. It correctly classifies the case, ensures high specificity by making architectural abnormality a mandatory requirement, and uses explicit thresholds.\n\n**Option C:**\n- **Algorithm:** Diagnose HCC if any $1$ of the following is present: median $N:C \\ge 0.55$ or $N_{\\text{prom}} \\ge 20\\%$ or $P_{\\text{thick}} \\ge 10\\%$.\n- **Evaluation:**\n    1. **Aim (a) - Explicit Thresholds:** This aim is met. The thresholds are $0.55$, $20\\%$, and $10\\%$.\n    2. **Aim (c) - Classify Case as HCC:**\n        - Is median $N:C \\ge 0.55$? Yes, $0.55 \\ge 0.55$.\n        Since only one criterion is needed, this algorithm diagnoses the case as HCC. This aim is met.\n    3. **Aim (b) - Specificity  Prioritizing Architecture:** The \"any $1$\" (logical OR) structure is a major flaw. It allows for an HCC diagnosis based on any single feature, including cytologic features alone. This directly contravenes the principle of prioritizing architecture to distinguish from reactive atypia. For example, a reactive nodule with a median $N:C$ of $0.56$ but no other abnormalities would be incorrectly diagnosed as HCC. This aim is not met.\n- **Verdict:** Incorrect. The algorithm fails to satisfy Aim (b) due to its \"OR\" logic, which results in low specificity.\n\n**Option D:**\n- **Algorithm:** Diagnose HCC only if all $3$ of the following stricter thresholds are met: median $N:C \\ge 0.60$; $N_{\\text{prom}} \\ge 25\\%$; $P_{\\text{thick}} \\ge 30\\%$.\n- **Evaluation:**\n    1. **Aim (a) - Explicit Thresholds:** This aim is met. The thresholds are $0.60$, $25\\%$, and $30\\%$.\n    2. **Aim (c) - Classify Case as HCC:**\n        - Is median $N:C \\ge 0.60$? No, $0.55  0.60$.\n        - Is $N_{\\text{prom}} \\ge 25\\%$? Yes, $25\\% \\ge 25\\%$.\n        - Is $P_{\\text{thick}} \\ge 30\\%$? Yes, $30\\% \\ge 30\\%$.\n        Since the algorithm requires all three criteria to be met, and the $N:C$ criterion is not met, this algorithm does not diagnose the case as HCC. This aim is not met.\n    3. **Aim (b) - Specificity  Prioritizing Architecture:** This algorithm requires all three features, including the architectural one, and sets very high thresholds. It would have excellent specificity. This aim is met. However, failing Aim (c) is a disqualifier.\n- **Verdict:** Incorrect. The algorithm is too strict and fails to classify the given case as HCC, thus failing to meet Aim (c).\n\n**Conclusion:**\nOnly Option B successfully meets all three required aims: it uses explicit thresholds, prioritizes architectural derangement to ensure high specificity against benign mimics, and correctly classifies the specified biopsy as HCC.", "answer": "$$\\boxed{B}$$", "id": "4380843"}, {"introduction": "After a diagnosis of hepatocellular carcinoma is made, assessing its grade is essential for predicting its biological behavior and guiding management. The Edmondson-Steiner grading system provides a morphological framework for this assessment by evaluating the tumor's degree of differentiation, from well-differentiated tumors that resemble normal liver tissue to poorly differentiated ones that have lost all resemblance. This exercise helps connect the microscopic appearance of a tumor (cytologic atypia and architectural pattern) to its underlying proliferative activity, as measured by the Ki-67 labeling index, reinforcing the principle that histologic grade is a direct reflection of a tumor's aggressiveness [@problem_id:4380791].", "problem": "A pathology service evaluates a resection-proven hepatocellular carcinoma (HCC) cohort using the Edmondson-Steiner grading scheme and the proliferation marker Ki-67 measured by immunohistochemistry. The team wants a principled statement that both defines the grades based on cytologic atypia and architectural disorder and predicts how the Ki-67 labeling index should change across grades given that the index reports the fraction of cycling tumor cells. Which option best meets this objective while staying consistent with well-established tumor grading principles and the biologic meaning of Ki-67?\n\nA. Edmondson-Steiner grade I is defined by well-differentiated features, including thin trabeculae ($1$-$2$ cells thick), bile production, and minimal nuclear atypia; grade II shows moderately differentiated features with thickened trabeculae (commonly $3$-$4$ cells), pseudoglandular areas, and moderate atypia; grades III–IV show poorly differentiated to undifferentiated features with solid sheets, severe architectural loss, marked pleomorphism, and frequent mitoses. Across grades I to IV, the Ki-67 labeling index progressively increases because it identifies cells in active cell-cycle phases ($G_1$, $S$, $G_2$, and $M$) but not quiescent ($G_0$), so higher cytologic atypia and architectural disorder reflect a larger cycling fraction.\n\nB. Edmondson-Steiner grades are primarily determined by tumor size and macrovascular invasion, and Ki-67 is expected to inversely correlate with grade because well-differentiated tumors proliferate more rapidly than undifferentiated ones.\n\nC. Grade II tumors typically have predominant pseudoglandular architecture with low atypia and a Ki-67 labeling index $10\\%$, while grade I tumors display severe pleomorphism and a Ki-67 labeling index $40\\%$.\n\nD. Ki-67 is a marker of apoptosis; therefore, higher grade tumors with more necrosis show lower Ki-67 indices despite worse cytology and architecture.\n\nE. Architectural disorder peaks at grade II due to trabecular thickening, but grades III–IV partially regain architecture as cells become anaplastic; Ki-67 increases until grade II and then plateaus regardless of further cytologic atypia.", "solution": "The reasoning must start from fundamental principles of tumor grading and the biologic basis of the Ki-67 labeling index. In the Edmondson-Steiner schema for hepatocellular carcinoma, grading is based on the degree of differentiation, which is assessed through cytologic atypia and architectural pattern. The core definitions include:\n\n- Differentiation and cytologic atypia: Well-differentiated tumors recapitulate normal hepatocyte morphology with minimal nuclear pleomorphism, small nucleoli, and low mitotic rates. Poorly differentiated tumors show marked pleomorphism, hyperchromasia, prominent nucleoli, and frequent mitoses.\n- Architectural order: Well-differentiated hepatocellular carcinoma maintains hepatic architecture, such as thin trabeculae ($1$-$2$ cells thick), bile production, and recognizable sinusoidal organization. With increasing grade, trabeculae thicken (commonly $3$-$4$ cells), pseudoglandular patterns appear, and at high grades the architecture is lost, forming solid sheets and undifferentiated patterns including spindle or giant cell morphology.\n- Ki-67 biology: The Ki-67 antigen is expressed in cells actively cycling through $G_1$, $S$, $G_2$, and $M$ phases and is absent in $G_0$ (quiescent). Thus, the Ki-67 labeling index quantifies the proportion of cells in the cell cycle. A larger cycling fraction is expected in more aggressive, less differentiated tumors, which typically show higher mitotic activity and faster growth.\n\nFrom these principles, the expected pattern is that as grade increases from I to IV, cytologic atypia increases and architectural order decreases, and the Ki-67 labeling index increases because more cells are cycling. Typical ranges are variable by cohort, but a qualitative trend often observed is roughly lower indices in well-differentiated tumors (for example, approximately $10$-$15\\%$), intermediate in moderately differentiated (for example, approximately $15$-$30\\%$), and higher in poorly differentiated or undifferentiated tumors (for example, approximately $30\\%$), acknowledging biological and methodological variability.\n\nOption-by-option analysis:\n\nA. This option correctly defines grade I as well differentiated with thin trabeculae ($1$-$2$ cells thick), bile production, and minimal atypia; grade II as moderately differentiated with trabecular thickening (commonly $3$-$4$ cells), pseudoglandular areas, and moderate atypia; and grades III–IV as poorly differentiated to undifferentiated with solid sheets, severe architectural loss, marked pleomorphism, and frequent mitoses. It also correctly states the biologic basis for Ki-67: positivity in $G_1$, $S$, $G_2$, and $M$, absence in $G_0$, and therefore a progressive increase in labeling index with increasing grade as the cycling fraction grows. Verdict — Correct.\n\nB. This option confuses grading with staging. Tumor size and macrovascular invasion are staging parameters, not grading criteria. Moreover, the claim that Ki-67 inversely correlates with grade is opposite to the expected relationship; undifferentiated tumors generally have higher proliferative activity. Verdict — Incorrect.\n\nC. This option misassigns architectural and cytologic features to grades. Grade II does not inherently imply low atypia with a Ki-67 labeling index $10\\%$; such low indices are more consistent with well-differentiated tumors. Severe pleomorphism and very high Ki-67 (for example, $40\\%$) are features expected of high-grade (III–IV), not grade I. Verdict — Incorrect.\n\nD. This option misstates the biology of Ki-67. Ki-67 is not a marker of apoptosis; it marks proliferation. Necrosis and apoptosis do not directly cause lower Ki-67; in fact, higher grade tumors often have higher Ki-67 due to increased proliferation, even if they also show necrosis. Verdict — Incorrect.\n\nE. This option incorrectly suggests architectural disorder peaks at grade II and that grades III–IV regain architecture, which is contrary to the definition; disorder progresses with grade, and undifferentiation means architecture is lost, not regained. The assertion of Ki-67 plateauing after grade II also lacks biologic support; proliferative fraction typically continues to rise with increasing grade. Verdict — Incorrect.\n\nTherefore, the option that correctly defines Edmondson-Steiner grades and relates cytologic atypia and architectural disorder to Ki-67 proliferative indices is option A.", "answer": "$$\\boxed{A}$$", "id": "4380791"}]}